In the midst of shifting political headwinds and a tight funding market, many life sciences companies are considering their M&A exit. Potential acquirers (both strategic and private equity) have plenty of dry powder and are...more
7/17/2025
/ Acquisition Agreements ,
Collaboration ,
Confidential Information ,
Corporate Sales Transactions ,
Due Diligence ,
Intellectual Property Protection ,
IP License ,
Life Sciences ,
Merger Agreements ,
Private Equity ,
Valuation